EMEA: Revenue grew 21% in Q4, driven by service and instruments for academic and government customers; management noted weaker demand from biotech, pharma, and CRO customers.U.S.: Total revenue grew 5% in Q4, driven by double-digit service revenue growth. McCombe said U.S. instrument revenue was flat, with strength in academic and government offset by softer demand from biotech and pharma.Management reported double-digit year-over-year revenue growth in both EMEA and APAC during the fourth quarter, with mid ...